天康生物
(002100)
| 流通市值：100.89亿 | | | 总市值：100.89亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 13,610,370,203.12 | 8,846,725,199.5 | 4,180,253,944.24 | 17,175,805,190.11 |
| 营业收入 | 13,610,370,203.12 | 8,846,725,199.5 | 4,180,253,944.24 | 17,175,805,190.11 |
| 二、营业总成本 | 13,098,483,091.04 | 8,435,393,584.63 | 4,012,088,136.8 | 16,479,483,378.21 |
| 营业成本 | 12,129,821,528.94 | 7,778,921,232.32 | 3,685,986,705.54 | 15,090,298,865.63 |
| 税金及附加 | 35,746,600.1 | 24,744,843.34 | 12,155,303.45 | 47,054,072.14 |
| 销售费用 | 294,881,912.31 | 203,244,468.02 | 105,364,201.59 | 427,635,411.73 |
| 管理费用 | 370,467,316.92 | 240,358,633.09 | 121,200,724.44 | 559,620,695.66 |
| 研发费用 | 164,593,119.84 | 112,870,560.82 | 50,150,345.89 | 200,252,390.3 |
| 财务费用 | 102,972,612.94 | 75,253,847.04 | 37,230,855.89 | 154,621,942.75 |
| 其中:利息费用 | 112,841,990.57 | 80,437,905 | 39,756,510.02 | 178,940,936.76 |
| 其中:利息收入 | 18,852,558.07 | 15,044,762.17 | -8,321,946.2 | 38,644,572.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 354,952.96 | 44,621.09 | -26,478.3 | 50,872.22 |
| 加:投资收益 | -9,492,630.37 | -7,276,145.63 | -7,557,835.32 | -1,917,176.15 |
| 资产处置收益 | -192,326.85 | -423,913.1 | -1,641,062.85 | 4,500,658.4 |
| 资产减值损失(新) | -4,094,463.56 | -3,186,193.54 | -536,573.35 | -22,737,961.15 |
| 信用减值损失(新) | -38,433,637.16 | -25,977,698.18 | -21,136,956.4 | -109,418,167.84 |
| 其他收益 | 41,972,572.82 | 29,438,316.98 | 17,449,920.54 | 64,309,885.27 |
| 四、营业利润 | 502,001,579.92 | 403,950,602.49 | 154,716,821.76 | 631,109,922.65 |
| 加:营业外收入 | 41,809,484.34 | 38,044,983.52 | 25,508,794.1 | 30,113,385.71 |
| 减:营业外支出 | 28,417,541.11 | 21,011,245.68 | 7,692,039.35 | 50,410,872.72 |
| 五、利润总额 | 515,393,523.15 | 420,984,340.33 | 172,533,576.51 | 610,812,435.64 |
| 减:所得税费用 | 10,528,434.89 | 11,366,210.93 | 1,092,034.48 | 14,391,247.6 |
| 六、净利润 | 504,865,088.26 | 409,618,129.4 | 171,441,542.03 | 596,421,188.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 504,865,088.26 | 409,618,129.4 | 171,441,542.03 | 596,421,188.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 411,749,486.05 | 338,289,250.51 | 148,142,983.18 | 605,052,882.38 |
| 少数股东损益 | 93,115,602.21 | 71,328,878.89 | 23,298,558.85 | -8,631,694.34 |
| 扣除非经常损益后的净利润 | 381,756,447.68 | 314,216,916.15 | 128,426,493.9 | 558,836,996.66 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 0.25 | 0.11 | 0.44 |
| (二)稀释每股收益 | 0.3 | 0.25 | 0.11 | 0.44 |
| 八、其他综合收益 | 42,755,441.21 | -25,190,790.19 | -41,188,202.22 | 225,776.62 |
| 归属于母公司股东的其他综合收益 | 42,732,831.34 | -25,301,278.85 | -41,212,253.56 | -57,921.96 |
| 九、综合收益总额 | 547,620,529.47 | 384,427,339.21 | 130,253,339.81 | 596,646,964.66 |
| 归属于母公司股东的综合收益总额 | 454,482,317.39 | 312,987,971.66 | 106,930,729.62 | 604,994,960.42 |
| 归属于少数股东的综合收益总额 | 93,138,212.08 | 71,439,367.55 | 23,322,610.19 | -8,347,995.76 |
| 公告日期 | 2025-10-30 | 2025-08-30 | 2025-04-30 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |